Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES

BACKGROUND: Lowering of atherogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of ischemic stroke. However, concerns have been raised about very low LDL-C levels and a potential increased risk of hemorrhagic stroke. ODYSSEY OUTCOMES compared the PCSK9 inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Jukema, J. Wouter, Zijlstra, Laurien E., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Drexel, Heinz, Goodman, Shaun G., Kim, Yong-Un, Pordy, Robert, Reiner, Željko, Roe, Matthew T., Tse, Hung-Fat, Montenegro Valdovinos, Pablo Carlos, White, Harvey D., Zeiher, Andreas M., Szarek, Michael, Schwartz, Gregory G., Steg, Philippe Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919220/
https://www.ncbi.nlm.nih.gov/pubmed/31707788
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.043826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6919220/
https://www.ncbi.nlm.nih.gov/pubmed/31707788
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.043826

Ejemplares similares